Related Experiment Video
Updated: May 4, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
29.3K
[Our experience with targeted therapy in glioblastoma multiforme]
Edina Kiss1, Erika Lahm1, József Vachaja1
1Onkológiai Osztály, MH Egészségügyi Központ, Budapest, Hungary. edina.kiss.dobos@gmail.com.
Magyar Onkologia
|December 20, 2013
Summary
Bevacizumab is an effective adjuvant therapy for glioblastoma multiforme (GBM), a common brain cancer. This targeted treatment improved progression-free survival and was well-tolerated in newly diagnosed patients.
Area of Science:
- Neuro-oncology
- Medical oncology
- Cancer research
Background:
- Glioblastoma multiforme (GBM) is the most aggressive primary adult brain tumor.
- Standard treatment involves surgery, radiation, and temozolomide chemotherapy.
- Bevacizumab is the sole recommended therapy for recurrent or progressive GBM.
Purpose of the Study:
- Evaluate clinical response and side effects of bevacizumab in newly diagnosed GBM patients.
- Compare local treatment data with international findings.
- Assess the efficacy of targeted adjuvant therapy.
Main Methods:
- Retrospective analysis of patient data from the department.
- Evaluation of clinical response, progression-free survival (PFS), and overall survival.
- Comparison with published data, including the AVAglio study.
Main Results:
- The treatment protocol was well-tolerated by patients.
- Observed side effects aligned with previously reported profiles.
- Median PFS and survival data were consistent with existing literature.
- The AVAglio study confirmed bevacizumab's significant PFS increase.
Conclusions:
- Adjuvant bevacizumab demonstrates a favorable safety and efficacy profile in newly diagnosed GBM.
- Local data supports international findings on bevacizumab's role in improving PFS.
- Bevacizumab represents a valuable targeted therapy option for glioblastoma.
